Studies Highlight Utility of Virologic Assays in HIV Management at 12th Conference on Retroviruses and Opportunistic Infections

Studies Highlight Utility of Virologic Assays in HIV Management
at 12th Conference on Retroviruses and Opportunistic Infections 


SOUTH SAN FRANCISCO, Calif., Feb. 28  /PRNewswire-FirstCall/ -- ViroLogic, Inc.
(NASDAQ:VLGC) announced today that 20 presentations related to its
sophisticated tests characterizing replication capacity (RC), viral tropism,
and phenotypic and genotypic resistance to anti-HIV drugs were made at the 12th
Conference on Retroviruses and Opportunistic Infections (CROI), which took
place this week in Boston.

"These studies highlight the importance of ViroLogic's tests for resistance, RC
and tropism in the effective management of HIV patients and the development of
new HIV drugs and vaccines," stated Christos Petropoulos, Ph.D., Vice President
of Research and Development at ViroLogic. "ViroLogic is expanding the field of
knowledge about HIV and is the collaboration partner of choice for
pharmaceutical companies and researchers."

  Among the highlights of this year's presentations:

   * Two studies used ViroLogic's RC assay to assess the role of viral
     fitness in HIV disease progression during antiretroviral therapy. These
     studies evaluated the use of the RC assay as a  predictor of immune
     system recovery;
   * Seven presentations included data generated using ViroLogic's
     proprietary entry susceptibility and co-receptor tropism assays, which
     measure viral susceptibility to entry inhibitors, and identify the
     preferred cell receptors for HIV for virus entry, respectively.
     Several of these studies show ViroLogic's expanding capability to
     support the numerous biopharmaceutical companies now developing entry
     inhibitor drugs to treat HIV; and
   * Six presentations used ViroLogic's PhenoSense GT(TM), PhenoSense(TM)
     HIV and GeneSeq(TM) HIV assays to further our understanding of
     resistance to a number of current drugs and to determine the clinical
     utility of combined resistance testing in the selection of
     antiretroviral regimens.

  About ViroLogic


ViroLogic is a biotechnology company advancing individualized medicine by
discovering, developing and marketing innovative products to guide and improve
treatment of serious infectious diseases and cancer. The Company's products are
designed to help doctors optimize treatment regimens for their patients that
lead to better outcomes and reduced costs. The Company's technology is also
being used by numerous biopharmaceutical companies to develop new and improved
antiviral therapeutics and vaccines as well as targeted cancer therapeutics.
More information about the Company and its technology can be found on its web
site at http://www.virologic.com/.

FORWARD LOOKING STATEMENTS

Certain statements in this press release are forward-looking, including
statements regarding the role for ViroLogic's tests and tests in development in
guiding the therapy of HIV-infected patients. These forward-looking statements
are subject to risks and uncertainties and other factors, which may cause
actual results to differ materially from the anticipated results or other
expectations expressed in such forward-looking statements. These risks and
uncertainties include, but are not limited to, risks and uncertainties relating
to the performance of our products; our ability to successfully conduct
clinical studies and the results obtained from those studies; whether larger
confirmatory clinical studies will confirm the results of initial studies; our
ability to establish reliable, high-volume operations at commercially
reasonable costs; expected reliance on a few customers for the majority of our
revenues; the annual renewal of certain customer agreements; actual market
acceptance of our products and adoption of our technological approach and
products by pharmaceutical and biotechnology companies; our estimate of the
size of our markets; our estimates of the levels of demand for our products;
the timing and ultimate size of pharmaceutical company clinical trials; whether
payors will authorize reimbursement for its products; whether the FDA or any
other agency will decide to regulate ViroLogic's products or services; whether
the Company will encounter problems or delays in automating its processes;
whether intellectual property underlying the Company's technologies is
adequate; whether licenses to third party technology will be available; and,
whether we are able to build brand loyalty and expand revenues. For a
discussion of other factors that may cause ViroLogic's actual events to differ
from those projected, please refer to the Company's most recent annual report
on Form 10-K and quarterly reports on Form 10-Q, as well as other subsequent
filings with the Securities and Exchange Commission. 

DATASOURCE: ViroLogic, Inc.



CONTACT:  Alfred Merriweather, Vice President and CFO of ViroLogic,

[phone]; or Carolyn Bumgardner Wang of WeissComm Partners,

[phone], or , for ViroLogic



Web site:  http://www.virologic.com/ 

Copyright